open access

Vol 14, No 2 (2019)
Heart failure
Published online: 2019-05-22
Get Citation

A break in pharmacotherapy with empagliflozin in a patient with heart failure with reduced ejection fraction and hospitalization caused by exacerbation of heart failure

Agnieszka Komorowska, Małgorzata Lelonek
DOI: 10.5603/FC.2019.0039
·
Folia Cardiologica 2019;14(2):199-205.

open access

Vol 14, No 2 (2019)
Heart failure
Published online: 2019-05-22

Abstract

A 56 year-old man with severe dysfunction was admitted to the Department due to exacerbation of chronic heart failure with reduced left ventricular ejection fraction. During hospitalization the standard treatment of heart failure was used, but also there was a modification of pharmacotherapy in diabetes. Based on the clinical case description, the article shows the current state of knowledge on the beneficial effects of empagliflozin on the cardiovascular system. 

Abstract

A 56 year-old man with severe dysfunction was admitted to the Department due to exacerbation of chronic heart failure with reduced left ventricular ejection fraction. During hospitalization the standard treatment of heart failure was used, but also there was a modification of pharmacotherapy in diabetes. Based on the clinical case description, the article shows the current state of knowledge on the beneficial effects of empagliflozin on the cardiovascular system. 

Get Citation

Keywords

heart failure with reduced ejection fraction; empagliflozin

About this article
Title

A break in pharmacotherapy with empagliflozin in a patient with heart failure with reduced ejection fraction and hospitalization caused by exacerbation of heart failure

Journal

Folia Cardiologica

Issue

Vol 14, No 2 (2019)

Pages

199-205

Published online

2019-05-22

DOI

10.5603/FC.2019.0039

Bibliographic record

Folia Cardiologica 2019;14(2):199-205.

Keywords

heart failure with reduced ejection fraction
empagliflozin

Authors

Agnieszka Komorowska
Małgorzata Lelonek

References (14)
  1. Ponikowski P, Voors A, Anker S, et al. Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiol Pol. 2016; 74(10): 1037–1147.
  2. McMurray JJV. Clinical practice. Systolic heart failure. N Engl J Med. 2010; 362(3): 228–238.
  3. Dunlay SM, Redfield MM, Weston SA, et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol. 2009; 54(18): 1695–1702.
  4. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34(1): 29–34.
  5. Metra M, Zacà V, Parati G, et al. Heart Failure Study Group of the Italian Society of Cardiology. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. J Cardiovasc Med (Hagerstown). 2011; 12(2): 76–84.
  6. Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018; 61(1): 21–28.
  7. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014; 53(3): 213–225.
  8. Butler J, Hamo CE, Filippatos G, et al. EMPEROR Trials Program. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2017; 19(11): 1390–1400.
  9. Baptist G. The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 Inhibitors — real-world data. Eur Endocrinol. 2018; 14(1): 17–23.
  10. Fitchett D, Zinman B, Wanner C, et al. EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016; 37(19): 1526–1534.
  11. Kosiborod M, Lam CSP, Kohsaka S, et al. CVD-REAL Investigators and Study Group. Cardiovascular events associated with SGLT-2 Iihibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018; 71(23): 2628–2639.
  12. Kaplan A, Abidi E, El-Yazbi A, et al. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. Heart Fail Rev. 2018; 23(3): 419–437.
  13. Das SR, Everett BM, Birtcher KK, et al. 2018 ACC Expert Consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018; 72(24): 3200–3223.
  14. Wiviott SD, Raz I, Bonaca MP, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347–357.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl